{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:34:51Z","timestamp":1775586891653,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30772824"],"award-info":[{"award-number":["30772824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30772824"],"award-info":[{"award-number":["30772824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thyroid eye disease (TED), an autoimmune inflammatory disorder affecting the orbit, exhibits a range of clinical manifestations. While the disease presentation can vary, cases that adhere to a prototypical pattern typically commence with mild symptoms that subsequently escalate in severity before entering a phase of stabilization. Notably, the metabolic activity of cells implicated in the disease substantially deviates from that of healthy cells, with purine metabolism representing a critical facet of cellular material metabolism by supplying components essential for DNA and RNA synthesis. Nevertheless, the precise involvement of Purine Metabolism Genes (PMGs) in the defensive mechanism against TED remains largely unexplored. The present study employed a bioinformatics approach to identify and validate potential PMGs associated with TED. A curated set of 65 candidate PMGs was utilized to uncover novel PMGs through a combination of differential expression analysis and a PMG dataset. Furthermore, GSEA and GSVA were employed to explore the biological functions and pathways associated with the newly identified PMGs. Subsequently, the Lasso regression and SVM-RFE algorithms were applied to identify hub genes and assess the diagnostic efficacy of the top 10 PMGs in distinguishing TED. Additionally, the relationship between hub PMGs and clinical characteristics was investigated. Finally, the expression levels of the identified ten PMGs were validated using the GSE58331 and GSE105149 datasets. This study revealed ten PMGs related with TED. PRPS2, PFAS, ATIC, NT5C1A, POLR2E, POLR2F, POLR3B, PDE3A, ADSS, and NTPCR are among the PMGs. The biological function investigation revealed their participation in processes such as RNA splicing, purine-containing chemical metabolism, and purine nucleotide metabolism. Furthermore, the diagnostic performance of the 10 PMGs in differentiating TED was encouraging. This study was effective in identifying ten PMGs linked to TED. These findings provide light on potential new biomarkers for TED and open up possibilities for tracking disease development.<\/jats:p>","DOI":"10.1038\/s41598-023-45048-9","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:02:14Z","timestamp":1698339734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Purine metabolism-related genes and immunization in thyroid eye disease were validated using bioinformatics and machine learning"],"prefix":"10.1038","volume":"13","author":[{"given":"Zixuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"9","key":"45048_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1503\/cmaj.121815","volume":"185","author":"MJ Belliveau","year":"2013","unstructured":"Belliveau, M. J. & Jordan, D. R. Thyroid eye disease. CMAJ 185(9), 797. https:\/\/doi.org\/10.1503\/cmaj.121815 (2013).","journal-title":"CMAJ"},{"issue":"8","key":"45048_CR2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar, S. et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond) 36(8), 1553\u20131559. https:\/\/doi.org\/10.1038\/s41433-021-01593-z (2022).","journal-title":"Eye (Lond)"},{"key":"45048_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","volume":"107","author":"L Girnita","year":"2022","unstructured":"Girnita, L., Smith, T. J. & Janssen, J. It takes two to Tango: IGF-I and TSH receptors in thyroid eye disease. J. Clin. Endocrinol. Metab. 107, S1\u2013S12. https:\/\/doi.org\/10.1210\/clinem\/dgac045 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"45048_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cxo.12472","volume":"100","author":"DL Weiler","year":"2017","unstructured":"Weiler, D. L. Thyroid eye disease: a review. Clin. Exp. Optom. 100(1), 20\u201325. https:\/\/doi.org\/10.1111\/cxo.12472 (2017).","journal-title":"Clin. Exp. Optom."},{"issue":"4","key":"45048_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl. J. Med. 382(4), 341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434 (2020).","journal-title":"N Engl. J. Med."},{"issue":"17","key":"45048_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","volume":"82","author":"T Nie","year":"2022","unstructured":"Nie, T. & Lamb, Y. N. Teprotumumab: a review in thyroid eye disease. DRUGS 82(17), 1663\u20131670. https:\/\/doi.org\/10.1007\/s40265-022-01804-1 (2022).","journal-title":"DRUGS"},{"issue":"2","key":"45048_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ceo.13899","volume":"49","author":"AP Jain","year":"2021","unstructured":"Jain, A. P., Jaru-Ampornpan, P. & Douglas, R. S. Thyroid eye disease: redefining its management-A review. Clin. Exp. Ophthalmol. 49(2), 203\u2013211. https:\/\/doi.org\/10.1111\/ceo.13899 (2021).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"45048_CR8","doi-asserted-by":"publisher","first-page":"970386640","DOI":"10.1177\/25158414211027760","volume":"13","author":"CJ Men","year":"2021","unstructured":"Men, C. J., Kossler, A. L. & Wester, S. T. Updates on the understanding and management of thyroid eye disease. Ther. Adv. Ophthalmol. 13, 970386640. https:\/\/doi.org\/10.1177\/25158414211027760 (2021).","journal-title":"Ther. Adv. Ophthalmol."},{"key":"45048_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-3-030-59038-3_21","volume":"1296","author":"DH Jo","year":"2020","unstructured":"Jo, D. H., Kim, J. H. & Kim, J. H. Tumor environment of retinoblastoma intraocular cancer. Adv. Exp. Med. Biol. 1296, 349\u2013358. https:\/\/doi.org\/10.1007\/978-3-030-59038-3_21 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"45048_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20(1), 28. https:\/\/doi.org\/10.1186\/s12943-021-01316-8 (2021).","journal-title":"Mol. Cancer"},{"issue":"8","key":"45048_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. Immunol. 17(8), 807\u2013821. https:\/\/doi.org\/10.1038\/s41423-020-0488-6 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"45048_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.942267","volume":"13","author":"S Yang","year":"2022","unstructured":"Yang, S. et al. A novel purine and uric metabolism signature predicting the prognosis of hepatocellular carcinoma. Front. Genet. 13, 942267. https:\/\/doi.org\/10.3389\/fgene.2022.942267 (2022).","journal-title":"Front. Genet."},{"issue":"1","key":"45048_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13048-022-01022-z","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Targeting purine metabolism in ovarian cancer. J. Ovarian Res. 15(1), 93. https:\/\/doi.org\/10.1186\/s13048-022-01022-z (2022).","journal-title":"J. Ovarian Res."},{"key":"45048_CR14","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3389\/fimmu.2018.01697","volume":"9","author":"J Yin","year":"2018","unstructured":"Yin, J. et al. Potential mechanisms connecting purine metabolism and cancer therapy. Front. Immunol. 9, 1697. https:\/\/doi.org\/10.3389\/fimmu.2018.01697 (2018).","journal-title":"Front. Immunol."},{"issue":"3","key":"45048_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.18097\/PBMC20166203302","volume":"62","author":"OP Shatova","year":"2016","unstructured":"Shatova, O. P. et al. Metformin impact on purine metabolism in breast cancer. Biomed. Khim. 62(3), 302\u2013305 (2016).","journal-title":"Biomed. Khim."},{"issue":"3","key":"45048_CR16","doi-asserted-by":"publisher","DOI":"10.18097\/PBMC20166203302","volume":"114","author":"X Chen","year":"2022","unstructured":"Chen, X. & Chen, J. miR-10b-5p-mediated upregulation of PIEZO1 predicts poor prognosis and links to purine metabolism in breast cancer. Genomics 114(3), 110351. https:\/\/doi.org\/10.18097\/PBMC20166203302 (2022).","journal-title":"Genomics"},{"issue":"2","key":"45048_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling, P. R. et al. Secondary osteoporosis. Endocr. Rev. 43(2), 240\u2013313. https:\/\/doi.org\/10.1210\/endrev\/bnab028 (2022).","journal-title":"Endocr. Rev."},{"issue":"2","key":"45048_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.dcmed.2022.06.001","volume":"5","author":"ST Zhao","year":"2022","unstructured":"Zhao, S. T. et al. Visualization analysis of the international standard ISO\/TC 249 for traditional Chinese medicine. Dig. Chinese Med. 5(2), 103\u2013111 (2022).","journal-title":"Dig. Chinese Med."},{"issue":"1","key":"45048_CR19","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1038\/s41598-023-33277-x","volume":"13","author":"Z Wu","year":"2023","unstructured":"Wu, Z. et al. A novel Alzheimer\u2019s disease prognostic signature: identification and analysis of glutamine metabolism genes in immunogenicity and immunotherapy efficacy. Sci. Rep. 13(1), 6895. https:\/\/doi.org\/10.1038\/s41598-023-33277-x (2023).","journal-title":"Sci. Rep."},{"issue":"5","key":"45048_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12(5), 453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337 (2015).","journal-title":"Nat. Methods"},{"issue":"13","key":"45048_CR21","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/bioinformatics\/btx104","volume":"33","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., Topham, D. J., Thakar, J. & Qiu, X. FUNNEL-GSEA: FUNctioNal ELastic-net regression in time-course gene set enrichment analysis. Bioinformatics 33(13), 1944\u20131952. https:\/\/doi.org\/10.1093\/bioinformatics\/btx104 (2017).","journal-title":"Bioinformatics"},{"key":"45048_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7. https:\/\/doi.org\/10.1186\/1471-2105-14-7 (2013).","journal-title":"BMC Bioinform."},{"issue":"2","key":"45048_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","volume":"51","author":"TD Hoang","year":"2022","unstructured":"Hoang, T. D., Stocker, D. J., Chou, E. L. & Burch, H. B. 2022 update on clinical management of Graves disease and thyroid eye disease. Endocrinol. Metab. Clin. North Am. 51(2), 287\u2013304. https:\/\/doi.org\/10.1016\/j.ecl.2021.12.004 (2022).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"45048_CR24","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1210\/clinem\/dgac252","volume":"107","author":"G Barbesino","year":"2022","unstructured":"Barbesino, G., Salvi, M. & Freitag, S. K. Future projections in thyroid eye disease. J. Clin. Endocrinol. Metab. 107, S47\u2013S56. https:\/\/doi.org\/10.1210\/clinem\/dgac252 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"45048_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/bjophthalmol-2020-316051","volume":"105","author":"JJ Khong","year":"2021","unstructured":"Khong, J. J. & McNab, A. Medical treatment in thyroid eye disease in 2020. Br J. Ophthalmol. 105(3), 299\u2013305. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316051 (2021).","journal-title":"Br J. Ophthalmol."},{"issue":"3","key":"45048_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.eprac.2020.11.011","volume":"27","author":"MH Lee","year":"2021","unstructured":"Lee, M. H. et al. Risk factors of thyroid eye disease. Endocr. Pract. 27(3), 245\u2013253. https:\/\/doi.org\/10.1016\/j.eprac.2020.11.011 (2021).","journal-title":"Endocr. Pract."},{"key":"45048_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/life12122084","author":"R Rashad","year":"2022","unstructured":"Rashad, R., Pinto, R., Li, E., Sohrab, M. & Distefano, A. G. Thyroid eye disease. Life (Basel) https:\/\/doi.org\/10.3390\/life12122084 (2022).","journal-title":"Life (Basel)"},{"key":"45048_CR28","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee, S. et al. Familiarity breeds strategy in silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells-Basel 10, 1917 (2021).","journal-title":"Cells-Basel"},{"key":"45048_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113784","volume":"155","author":"K Yang","year":"2022","unstructured":"Yang, K., Li, J. & Tao, L. Purine metabolism in the development of osteoporosis. Biomed. Pharmacother. 155, 113784. https:\/\/doi.org\/10.1016\/j.biopha.2022.113784 (2022).","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"45048_CR30","doi-asserted-by":"publisher","first-page":"E827","DOI":"10.1152\/ajpendo.00378.2020","volume":"319","author":"M Furuhashi","year":"2020","unstructured":"Furuhashi, M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab 319(5), E827\u2013E834. https:\/\/doi.org\/10.1152\/ajpendo.00378.2020 (2020).","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"45048_CR31","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1093\/bib\/bby073","volume":"20","author":"F Yu","year":"2019","unstructured":"Yu, F. et al. Breast cancer prognosis signature: linking risk stratification to disease subtypes. Brief. Bioinform. 20(6), 2130\u20132140. https:\/\/doi.org\/10.1093\/bib\/bby073 (2019).","journal-title":"Brief. Bioinform."},{"key":"45048_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cca.2016.11.032","volume":"464","author":"Z Jiang","year":"2017","unstructured":"Jiang, Z. et al. Quantitative proteomic analysis reveals that proteins required for fatty acid metabolism may serve as diagnostic markers for gastric cancer. Clin. Chim. Acta 464, 148\u2013154. https:\/\/doi.org\/10.1016\/j.cca.2016.11.032 (2017).","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"45048_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajim.23454","volume":"66","author":"K Lucas","year":"2023","unstructured":"Lucas, K., Gaines, L., Paris-Davila, T. & Nylander-French, L. A. Occupational exposure and serum levels of per- and polyfluoroalkyl substances (PFAS): a review. Am. J. Ind. Med. 66(5), 379\u2013392. https:\/\/doi.org\/10.1002\/ajim.23454 (2023).","journal-title":"Am. J. Ind. Med."},{"key":"45048_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/toxics10020044","author":"E Panieri","year":"2022","unstructured":"Panieri, E., Baralic, K., Djukic-Cosic, D., Buha, D. A. & Saso, L. PFAS molecules: a major concern for the human health and the environment. Toxics https:\/\/doi.org\/10.3390\/toxics10020044 (2022).","journal-title":"Toxics"},{"issue":"11","key":"45048_CR35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.envres.2020.110690","volume":"23","author":"Y Cao","year":"2021","unstructured":"Cao, Y. & Ng, C. Absorption, distribution, and toxicity of per- and polyfluoroalkyl substances (PFAS) in the brain: a review. Environ. Sci. Process Impacts 23(11), 1623\u20131640. https:\/\/doi.org\/10.1016\/j.envres.2020.110690 (2021).","journal-title":"Environ. Sci. Process Impacts"},{"key":"45048_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2020.110690","volume":"194","author":"K Steenland","year":"2021","unstructured":"Steenland, K. & Winquist, A. PFAS and cancer, a scoping review of the epidemiologic evidence. Environ Res. 194, 110690. https:\/\/doi.org\/10.1016\/j.envres.2020.110690 (2021).","journal-title":"Environ Res."},{"key":"45048_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2019.115381","volume":"171","author":"E Gagliano","year":"2020","unstructured":"Gagliano, E., Sgroi, M., Falciglia, P. P., Vagliasindi, F. & Roccaro, P. Removal of poly- and perfluoroalkyl substances (PFAS) from water by adsorption: role of PFAS chain length, effect of organic matter and challenges in adsorbent regeneration. Water Res. 171, 115381. https:\/\/doi.org\/10.1016\/j.watres.2019.115381 (2020).","journal-title":"Water Res."},{"issue":"2B","key":"45048_CR38","first-page":"1221","volume":"28","author":"AG Antonacopoulou","year":"2008","unstructured":"Antonacopoulou, A. G. et al. POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?. Anticancer Res. 28(2B), 1221\u20131227 (2008).","journal-title":"Anticancer Res."},{"key":"45048_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.951197","volume":"14","author":"W Lin","year":"2022","unstructured":"Lin, W. et al. Identification of a 6-RBP gene signature for a comprehensive analysis of glioma and ischemic stroke: cognitive impairment and aging-related hypoxic stress. Front Aging Neurosci. 14, 951197. https:\/\/doi.org\/10.3389\/fnagi.2022.951197 (2022).","journal-title":"Front Aging Neurosci."},{"issue":"9","key":"45048_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137654","volume":"10","author":"JT Rosenbaum","year":"2015","unstructured":"Rosenbaum, J. T. et al. The role of the immune response in the pathogenesis of thyroid eye disease: a reassessment. PLOS ONE 10(9), e137654. https:\/\/doi.org\/10.1371\/journal.pone.0137654 (2015).","journal-title":"PLOS ONE"},{"key":"45048_CR41","doi-asserted-by":"publisher","first-page":"1728423","DOI":"10.1155\/2020\/1728423","volume":"2020","author":"R Nallu","year":"2020","unstructured":"Nallu, R., Madhavan, P., Chirch, L. & Luthra, P. Thyroid eye disease due to immune reconstitution inflammatory syndrome as a consequence of antiretroviral therapy in the setting of AIDS. Case Rep. Endocrinol. 2020, 1728423. https:\/\/doi.org\/10.1155\/2020\/1728423 (2020).","journal-title":"Case Rep. Endocrinol."},{"issue":"9","key":"45048_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/thy.2007.0407","volume":"18","author":"GM Lehmann","year":"2008","unstructured":"Lehmann, G. M., Feldon, S. E., Smith, T. J. & Phipps, R. P. Immune mechanisms in thyroid eye disease. Thyroid 18(9), 959\u2013965. https:\/\/doi.org\/10.1089\/thy.2007.0407 (2008).","journal-title":"Thyroid"},{"issue":"1","key":"45048_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","volume":"35","author":"O Sagiv","year":"2019","unstructured":"Sagiv, O. et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr. Surg. 35(1), 50\u201352. https:\/\/doi.org\/10.1097\/IOP.0000000000001161 (2019).","journal-title":"Ophthalmic Plast Reconstr. Surg."},{"issue":"1","key":"45048_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40123-020-00317-y","volume":"10","author":"C Chau","year":"2021","unstructured":"Chau, C., Shih, K. C., Chow, L. & Lee, V. Considerations for use of immune checkpoint inhibitors in cancer therapy for patients with co-existing thyroid eye disease. Ophthalmol Ther. 10(1), 5\u201312. https:\/\/doi.org\/10.1007\/s40123-020-00317-y (2021).","journal-title":"Ophthalmol Ther."},{"issue":"1","key":"45048_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/tjo.tjo_51_21","volume":"12","author":"JS Yoon","year":"2022","unstructured":"Yoon, J. S. & Kikkawa, D. O. Thyroid eye disease: from pathogenesis to targeted therapies. Taiwan J. Ophthalmol. 12(1), 3\u201311. https:\/\/doi.org\/10.4103\/tjo.tjo_51_21 (2022).","journal-title":"Taiwan J. Ophthalmol."},{"key":"45048_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"Sears, C. M. et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am. J. Ophthalmol. 240, 1\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"45048_CR47","doi-asserted-by":"publisher","first-page":"7588084","DOI":"10.1155\/2022\/7588084","volume":"2022","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Identification of hub genes associated with nonspecific orbital inflammation by weighted gene coexpression network analysis. Dis. Markers 2022, 7588084. https:\/\/doi.org\/10.1155\/2022\/7588084 (2022).","journal-title":"Dis. Markers"},{"issue":"1","key":"45048_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40246-022-00412-0","volume":"16","author":"J Hu","year":"2022","unstructured":"Hu, J., Zhou, S. & Guo, W. Construction of the coexpression network involved in the pathogenesis of thyroid eye disease via bioinformatics analysis. Hum Genom. 16(1), 38. https:\/\/doi.org\/10.1186\/s40246-022-00412-0 (2022).","journal-title":"Hum Genom."},{"key":"45048_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858972","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang, J. & Zhou, Q. Gene biomarkers related to Th17 cells in macular edema of diabetic retinopathy: cutting-edge comprehensive bioinformatics analysis and in vivo validation. Front. Immunol. 13, 858972. https:\/\/doi.org\/10.3389\/fimmu.2022.858972 (2022).","journal-title":"Front. Immunol."},{"issue":"1","key":"45048_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"45048_CR51","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"D1","key":"45048_CR52","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51(D1), D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45048-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45048-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:05:09Z","timestamp":1698339909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45048-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45048"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45048-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18391"}}